RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

CTO - 7415
Cancer - Gastro/ Esophageal
  1. Adults at least 18 years of age
  2. Pathologically confirmed primary adenocarcinoma of the esophagus that involves the mid (up to 25 cm), distal, or esophagogastric junction; the cancer may involve the stomach up to 5 cm
  3. Endoscopy with biopsy
Open
Tiffany Pearce